Authors
Latest:
AUPN Leadership Minute Episode 37: International Physicians in NeurologyEpisode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]
Latest:
Diagnostic Criteria, Phenotypes and Epidemiology of Autoimmune Encephalitis: Divyanshu Dubey, MBBSThe assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]
Latest:
Factors to Consider When Choosing the Right Disease-Modifying Therapy for Newly Diagnosed MSGabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.
Latest:
Joaquim Ferreira, MD, PhD: The Magnitude of Effect for Opicapone in Parkinson DiseaseThe head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.
Latest:
Optimizing Care for SCN8A Epilepsy and Related Disorders: Gabi Conecker; JayEtta HeckerRepresentatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]
Latest:
Evolving Understanding and Treatment of Smoldering Multiple Sclerosis: Antonio Scalfari, MD, PhDThe consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]
Latest:
A National Registry Analysis on Minimally Invasive Surgery for Intracerebral Hemorrhage: Santosh Murthy, MD, MPHThe associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Latest:
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhDThe senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
Latest:
Stroke Intervention: A New Application of Interventional NeuroradiologyNew training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.
Latest:
Swallow This: Treating Dysphagia with Speech PathologyStephanie Richardson, MS, CCC-SLP, an outpatient lead speech-language pathologist at Brooks Rehabilitation, discussed the unique aspects of speech therapy and the pivotal role it plays in helping patients with swallowing and other related functions.
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
Latest:
The Outlook for Apitegromab and Its Phase 3 Trial: Yung Chyung, MDThe chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.
Latest:
Del-Zota Produced Statistically Significant Increases in Exon-Skipping and Dystrophin Levels in EXPLORE44, a Phase 1/2 Study in Individuals With DMD44MAravindhan Veerapandiyan, MD, discusses how del-zota (delpacibart zotadirsen), an exon 44 skipping agent using antibody-conjugated phosphorodiamidate morpholino oligomer (PMO) technology, demonstrated favorable safety, significant dystrophin production (25% of normal), and unprecedented reduction of creatine kinase levels to near-normal in patients with Duchenne muscular dystrophy (DMD) during phase 1/2 clinical trials.
Latest:
Using Brain Connectomes to Predict Disease Progression and Treatment Response in Multiple Sclerosis: Ceren Tozlu, PhDThe instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]
Latest:
Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhDThe neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
Latest:
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MDAs the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
Latest:
Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MDThe resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]
Latest:
Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer DiseaseThe professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.
Latest:
Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep ApneaRecent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
Latest:
Jan Hillert, MD, PhD: Stem Cell Transplants in MSThe professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.
Latest:
Potential Avenues for Combination Therapy in Obstructive Sleep Apnea: Danny Eckert, PhDThe director of sleep health at Flinders University in Australia explored how combination pharmacologic and noninvasive therapies may offer a personalized path forward in obstructive sleep apnea treatment. [WATCH TIME: 6 minutes]
Latest:
The Evolutionary Arch of Stereoelectroencephalography in the United StatesSEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.
Latest:
Alzheimer Disease: Separating Fact from FictionIn honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Latest:
Groundbreaking Epilepsy Research Studies on the Horizon in 2023: Anup Patel, MDThe pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]
Latest:
Jeffrey Buchhalter, MD: Disclosing SUDEP Risk to Patients With EpilepsyThe pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.
Latest:
2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MDThe codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]
